一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Giredestrant；Fulvestrant；Abemaciclib；Palbociclib；Ribociclib；LHRH Agonist；FoundationOne Liquid CDx Assay (F1LCDx)，当前状态为研究进行中，已停止招募。登记地点显示中国北京、长春、长沙、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Giredestrant；Fulvestrant；Abemaciclib；Palbociclib；Ribociclib；LHRH Agonist；FoundationOne Liquid CDx Assay (F1LCDx) · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- the First Hospital of Jilin University · 长春
- Hunan Cancer Hospital · 长沙
- West China Hospital of Sichuan University · 成都
- Sichuan Provincial People's Hospital · 成都
- Fujian Medical University Union Hospital · 福州
- No. 900 Hospital (Fuzhou General Hospital) · 福州
- Cancer Center, Sun Yat-sen University of Medical Sciences · 广州
- The Second Affiliated Hospital of Zhejiang University College · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Jinan Central Hospital · 济南
- Shandong Cancer Hospital · 济南
- The First People's Hospital of Yunnan Province · 昆明
- The First Affiliated Hospital to Henan University of Science and Technology · 洛阳
- Guangxi Cancer Hospital of Guangxi Medical University · 南宁
- Zhongshan Hospital Fudan University · 上海
- Fudan University Shanghai Cancer Center · 上海
- Shanxi Province Cancer Hospital · 太原
- Tianjin Cancer Hospital · 天津
- The Tumor Hospital of Xinjiang Medical University · 乌鲁木齐
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- Hubei Cancer Hospital · 武汉
- The Second Affiliated Hospital of Xi'an Jiao Tong University · 西安
- Xi'an International Medical Center Hospital · 西安
- The Affiliated Hospital of Xuzhou Medical University · 徐州
- Zhejiang Cancer Hospital · 浙江省
- The First Affiliated Hospital of Zhengzhou University · 郑州
公开的入选条件
- * Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
- * Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing)
- * Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing
- * Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after \>/=12 months or off-treatment within 12 months of completion. Prior use of adjuvant CDK4/6i is allowed (if relapse o
- * No prior systemic anti-cancer therapy for advanced disease
- * Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease
- * Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1
- * For pre/perimenopausal women and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06065748；登记信息更新于 2026-09-14。